News & Events
1859 Strengthens Leadership with Appointment of Consulting CSO and Strategic Pharma Advisors, Bringing Deep Oncology and Immunology Expertise
1859 is pleased to announce the appointment of Jeff Hager, Ph.D., as Consulting Chief Scientific Officer (CSO), and Michael Howell, Ph.D., and Venkat Reddy, Ph.D., as Strategic Pharma Advisors.
1859 Announces The Formation of Its Scientific Advisory Board
Appointees Include Two 2024 ACS National Award Recipients, AIML Trailblazer, and Serial Biotech Co-founder
1859 Welcomes Sanket Agrawal as New CEO
1859, an AI-based drug discovery company, appoints new CEO to drive strategic vision, expand development pipeline, and forge industry partnerships.
1859 Inc. Launches with $40 Million Series A to Industrialize New Medicine Discovery by Combining Artificial Intelligence and Empirical Screening Data at Scale
1859 Inc. is a platform company combining artificial intelligence and empirical screening data at scale to discover new small molecule medicines for emerging disease targets. The company partners with pharmaceutical and biotech companies, and academic institutions to dramatically shorten the time and resources needed to identify and screen high-potential compounds for future exploration and development.